New study in collaboration with the University of Siena demonstrates the exceptional bioavailability of Fe in Emosid compared to other products on the market

Curious about the latest breakthrough in iron supplements? What If a single supplement could outperform all others in terms of iron absorption and reduce common side effects? Introducing Emosid, a vegan iron supplement formulated with divalent ferrous sulphate and Vitamin C, encapsulated within...

Curious about the latest breakthrough in iron supplements?

What If a single supplement could outperform all others in terms of iron absorption and reduce common side effects?

Introducing Emosid, a vegan iron supplement formulated with divalent ferrous sulphate and Vitamin C, encapsulated within a patented liposomal bilayer structure known as Phytobilayer®. This innovative technology promises exceptional bioavailability and fewer side effects typically associated with oral iron intake.

Iron deficiency anemia, a condition affecting 1.2 billion people worldwide, often leads to fatigue, cognitive issues, and weight loss. Traditional iron supplements, though necessary, have limited absorption and can cause gastrointestinal distress. But Emosid offers a promising alternative.

How does it work? Emosid utilizes brand new patented delivery, enhancing iron absorption in the gut and preventing oxidation, which is responsible for the dark staining of teeth and stools. Its high bioavailability ensures more efficient uptake, even under conditions where the body’s iron needs are elevated, such as during pregnancy or menstruation.

But does it really outperform other supplements? A recent study by the University of Siena, published in March 2024 in the Journal of Drug Delivery Science and Technology, compared Emosid with six other iron-based products with different technologies. This comprehensive analysis revealed that Emosid had the highest bioavailability, with over 40% iron absorption, compared to 15-35% of other formulations. The liposomal form of iron in Emosid ensures superior absorption and reduced side effects, making it a standout choice for those seeking an effective iron supplement.

Why choose Emosid?

• Enhanced absorption: Thanks to the patented Phytobilayer® technology, Emosid ensures higher bioavailability of Fe2+.
• Reduced side effects: Its innovative formulation minimizes gastrointestinal discomfort.
• Comprehensive support: With added vitamins and copper, it supports overall iron metabolism and transport.

Curious to see if Emosid could be the solution to the iron deficiency? Dive into the details and get in touch with Oftalpharma to  discover how this groundbreaking supplement is setting a new standard in iron bioavailability

1.Cook JD, Finch CA, Smith NJ. Evaluation of the iron status of a population. Blood 1976; 48:449-55.
2. Goodnough LT, Skikne B, Brugnara C. Erythropoietin, iron and erythropoiesis. Blood 2000; 96:823-33.
3. Birgegard G, Hogman C, Killander A, et al. Serum ferritin and erythrocyte 2,3-DPG during quantitated phlebotomy and iron treatment. Scand J Haematol. 1977; 19:327-33. 4.Cook JD, Lipschitz DA, Miles LEM, et al. Serum ferritin as a measure of iron stores in normal subjects. Am J Clin Nutr 1974; 27:681-7.
5.Olsson KS, Marsell R, Ritter B, et al. Iron de ciency and iron overload in Swedish male adolescents. J Intern Med 1995; 237:187-94.
6.Huebers HA, Beguin Y, Pootrakul P, et al. Intact transferring receptors in human plasma and their relation erythropoiesis. Blood 1990; 75:102-7.
7. Brugnara C. Iron de ciency and erythropoiesis: new diagnostic approaches. Clin Chem 2003; 49:1573-8.
8. Guyatt GH, Patterson C, Ali M, Singer J, Levine M, Turpie I, et al. Diagnosis of iron de ciency anemia in the elderly. Am J Med 1990; 88:205-9.
9. Guyatt GH, Oxman AD, Willan A, McIlroy W, Patterson C. Laboratory diagnosis of ironde ciency anemia: an overview: J Gen Intern Med1992; 7;145-53
10. Doretto P, Cappelletti P. La diagnosi di laboratorio dell’anemia sideropenica RIMeL / IJLaM 2008; 4
11. Biochemistry, Iron Absorption Thomas Ems; Kayla St Lucia; Martin R. Huecker
12. Managing Genetic Hemochromatosis: An Overview of Dietary Measures, Which May Reduce Intestinal Iron Absorption in Persons With Iron Overload Nils Thorm Milman 13. https://doi.org/10.1016/j.jtemb.2012.03.015
13. «The great advantage of liposomes over other microencapsulation technologies is the stability liposomes impart to water-soluble material in high water activity application: spray- dryers,extruders, and fluidized beds impart great stability to food ingredients in the dry state but release their content readily in high water activity application,giving up all protection properties Recent Developments in Microencapsulation of Food Ingredients ; Kashappa Goud H. ; Drying Technology, 23: 1361–1394, 2005»
14. Liposomal Iron for Iron Deficiency Anemia in Women of Reproductive Age: Review of Current Evidence
Parag Biniwale1, Bhaskar Pal2, Tripura Sundari3, Gorakh Mandrupkar4 , Open Journal of Obstetrics and Gynecology, 2018, 8, 993-1005
) Liposomal Nanomedicine for Breast Cancer Therapy ; Shivani Rai Paliwal ; Nanomedicine. 2011;6(6):1085-1100
15) Effect of Combined Folic Acid, Vitamin B6,and Vitamin B12 on Cancer Risk in Women A Randomized Trial Shumin M. Zhang, MD, ScD ; JAMA. 2008;300(17):2012-2021
16) Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50 000 individuals; Stein Emil Vollset, Robert Clarke, Sarah Lewington ; www.thelancet.com Vol 381 March 23, 2013
17) Effect of Combined Folic Acid, Vitamin B6, and Vitamin B12 on Colorectal Adenoma ;Yiqing Song, JoAnn E. Manson ; Published by Oxford University Press. All rights reserved. accepted July 26, 2012
18) Helen A. Norman, The Role of Dietary Supplements during Cancer Therapy 1; J. Nutr. 133: 3794S–3799S, 2003.
19) ANTIOXIDANTS AND OTHER NUTRIENTS DO NOT INTERFERE WITH HEMOTHERAPY OR RADIATION THERAPY AND CAN INCREASE KILL AND INCREASE SURVIVAL, PART 2 ; Charles B. Simone II, MD; Nicole L. Simone; Altern Ther Health Med. 2007;13(2):40-46
20) L’ANEMIA IN ONCOLOGIA ; BARNI ; PRONZATO , ROSTI ; Copyright 2009 Wolters Kluwer Health Italy Ltd
21) Erythropoiesis stimulating agents (ESAs) e anemia nei pazienti affetti da disfunzione renale cronica; Ivano Baragetti ; Giornale Italiano di Farmacoeconomia e Farmacoutilizzazione 2013; 5 (3): 25-35
22) Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocysteinaemia in patients with uraemia ; The Lancet, Volume 361, Issue 9370 ; Ingrosso D. ,Cimino A.
23) Iperomocisteinemia e progressione delle nefropatie ; P. Finocchiaro ;Giornale Italiano di Nefrologia / Anno 22 n. 6, 2005 / pp. 590-596

24)Pepi, S., Talarico, L., Leone, G., Bonechi, C., Tamasi, G., Clemente, I., et al. (2024). Effect of oxidation state and chelating agent on iron bio-accessibility from different commercial iron-supplements. JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 94 [10.1016/j.jddst.2024.105535].